51
|
Chuang CH, Chuang KH, Wang HE, Roffler SR, Shiea JT, Tzou SC, Cheng TC, Kao CH, Wu SY, Tseng WL, Cheng CM, Hou MF, Wang JM, Cheng TL. In vivo positron emission tomography imaging of protease activity by generation of a hydrophobic product from a noninhibitory protease substrate. Clin Cancer Res 2011; 18:238-47. [PMID: 22019516 DOI: 10.1158/1078-0432.ccr-11-0608] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
PURPOSE To develop an imaging technology for protease activities in patients that could help in prognosis prediction and in design of personalized, protease-based inhibitors and prodrugs for targeted therapy. EXPERIMENTAL DESIGN Polyethylene glycol (PEG) was covalently attached to the N-terminus of a hydrophilic peptide substrate (GPLGVR) for matrix metalloproteinase (MMP) to increase hydrophilicity. PEG-peptide was then linked to a hydrophobic tetramethylrhodamine (TMR) domain and labeled with (18)F to form a PEG-peptide-(18)F-TMR probe. Specific cleavage of the probe by MMP2 was tested in vitro by matrix-assisted laser desorption/ionization-time-of-flight (MALDI-TOF). In vivo imaging of MMP2-expressing tumors was evaluated by micro-PET. RESULTS The hydrophobic TMR fragment (948 Da) was specifically generated by MMP2 enzymes and MMP-expressing HT1080 cells but not control MCF-7 cells. MMP-expressing HT1080 cells and tumors selectively accumulated the hydrolyzed, hydrophobic TMR fragment at sites of protease activity. Importantly, we found that (18)F-labeled probe ((18)F-TMR) preferentially localized in HT1080 tumors but not control MCF-7 tumors as shown by micro-PET. Uptake of the probe in HT1080 tumors was 18.4 ± 1.9-fold greater than in the MCF-7 tumors 30 minutes after injection. These results suggest that the PEG-peptide-(18)F-TMR probe displays high selectivity for imaging MMP activity. CONCLUSIONS This strategy successfully images MMP expression in vivo and may be extended to other proteases to predict patient prognosis and to design personalized, protease-based inhibitors and prodrug-targeted therapies.
Collapse
Affiliation(s)
- Chih-Hung Chuang
- Institute of Basic Medical Sciences, National Cheng Kung University, Tainan, Taiwan
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
52
|
Richardson PG, Lonial S, Jakubowiak AJ, Harousseau JL, Anderson KC. Monoclonal antibodies in the treatment of multiple myeloma. Br J Haematol 2011; 154:745-54. [PMID: 21777223 DOI: 10.1111/j.1365-2141.2011.08790.x] [Citation(s) in RCA: 63] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
Despite recent advances in treatment that have significantly improved overall survival, multiple myeloma (MM) remains incurable. Although rituximab, the first monoclonal antibody (MAb) evaluated in MM treatment, provided only very limited benefit, research is ongoing into a number of other MAbs directed against a variety of MM-related target antigens. Given the inherent immune dysfunction associated with MM, newer strategies that may enhance immune function in conjunction with antibodies may also provide a more fruitful clinical approach. Potential MAb targets in MM include growth factors and their receptors, other signalling molecules, and antigens expressed exclusively or predominantly on MM cells. MAb therapy involves a range of mechanisms, including antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, interference with receptor-ligand interactions, and MAb conjugation to radioisotopes or toxins. The antigens currently targeted in MM therapy are discussed, along with the development status of the corresponding MAb therapeutics. Elotuzumab, an anti-CS1 MAb, has recently achieved clinically meaningful responses when combined with lenalidomide or bortezomib in patients with relapsed and relapsed/refractory MM. Other MAbs are also showing early promise. More ongoing clinical research is required to identify optimal combination regimens and biomarkers that may help predict response to specific MAb-based combinations.
Collapse
Affiliation(s)
- Paul G Richardson
- Dana-Farber Cancer Institute, Boston, MA, USADepartment of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA, USAUniversity of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USACentre Rene Gauducheau, Nantes, France
| | | | | | | | | |
Collapse
|
53
|
|
54
|
Ona T, Shibata J. Advanced dynamic monitoring of cellular status using label-free and non-invasive cell-based sensing technology for the prediction of anticancer drug efficacy. Anal Bioanal Chem 2010; 398:2505-33. [DOI: 10.1007/s00216-010-4223-5] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/03/2010] [Revised: 08/24/2010] [Accepted: 09/13/2010] [Indexed: 12/26/2022]
|
55
|
Oh NM, Oh KT, Baik HJ, Lee BR, Lee AH, Youn YS, Lee ES. A self-organized 3-diethylaminopropyl-bearing glycol chitosan nanogel for tumor acidic pH targeting: In vitro evaluation. Colloids Surf B Biointerfaces 2010; 78:120-6. [DOI: 10.1016/j.colsurfb.2010.02.023] [Citation(s) in RCA: 51] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/10/2010] [Revised: 02/20/2010] [Accepted: 02/22/2010] [Indexed: 01/28/2023]
|
56
|
Abstract
PURPOSE Many anticancer therapies benefit only a subset of treated patients and may be overlooked by the traditional broad eligibility approach to design phase III clinical trials. New biotechnologies such as microarrays can be used to identify the patients that are most likely to benefit from anticancer therapies. However, due to the high-dimensional nature of the genomic data, developing a reliable classifier by the time the definitive phase III trail is designed may not be feasible. EXPERIMENTAL DESIGN Previously, Freidlin and Simon (Clinical Cancer Research, 2005) introduced the adaptive signature design that combines a prospective development of a sensitive patient classifier and a properly powered test for overall effect in a single pivotal trial. In this article, we propose a cross-validation extension of the adaptive signature design that optimizes the efficiency of both the classifier development and the validation components of the design. RESULTS The new design is evaluated through simulations and is applied to data from a randomized breast cancer trial. CONCLUSION The cross-validation approach is shown to considerably improve the performance of the adaptive signature design. We also describe approaches to the estimation of the treatment effect for the identified sensitive subpopulation.
Collapse
Affiliation(s)
- Boris Freidlin
- Biometric Research Branch, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland 20892, USA.
| | | | | |
Collapse
|
57
|
NISHIJIMA H, KOSAIHIRA A, SHIBATA J, ONA T. Development of Signaling Echo Method for Cell-based Quantitative Efficacy Evaluation of Anti-cancer Drugs in Apoptosis without Drug Presence Using High-precision Surface Plasmon Resonance Sensing. ANAL SCI 2010; 26:529-34. [DOI: 10.2116/analsci.26.529] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Affiliation(s)
- Hiroshi NISHIJIMA
- Graduate School of Bioresource and Bioenvironmental Sciences, Kyushu University
| | - Atsushi KOSAIHIRA
- Graduate School of Bioresource and Bioenvironmental Sciences, Kyushu University
| | - Junko SHIBATA
- Graduate School of Bioresource and Bioenvironmental Sciences, Kyushu University
| | - Toshihiro ONA
- Graduate School of Bioresource and Bioenvironmental Sciences, Kyushu University
| |
Collapse
|
58
|
Sobrero A, Bruzzi P. Incremental advance or seismic shift? The need to raise the bar of efficacy for drug approval. J Clin Oncol 2009; 27:5868-73. [PMID: 19826122 DOI: 10.1200/jco.2009.22.4162] [Citation(s) in RCA: 81] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
59
|
Rowinsky EK. Curtailing the High Rate of Late-Stage Attrition of Investigational Therapeutics Against Unprecedented Targets in Patients with Lung and Other Malignancies: Fig. 1. Clin Cancer Res 2009; 10:4220s-4226s. [PMID: 15217962 DOI: 10.1158/1078-0432.ccr-040013] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
A greater understanding of the pathogenesis and biology of cancer coupled with major advances in biotechnology has resulted in the identification of rationally designed, target-based (RDTB) anticancer therapeutics, ushering in new therapeutic opportunities and high expectations for the future as well as developmental challenges. Because these agents appear to principally target malignant cells, it is expected that they will produce less toxicity at clinically effective doses than nonspecific cytotoxic agents, but their target requirements are likely to be much more stringent. The innate complexity of the networks that contain elements targeted by these agents also decreases the probability that any single therapeutic manipulation will result in robust clinical activity and success when used alone, particularly in patients with solid malignancies that have multiple relevant signaling aberrations. In contrast, proof of principle and robust antitumor activity may be most efficiently demonstrated in nonrandomized evaluations involving tumors that are principally driven by aberrations of the specific target. The predominant therapeutic manifestation of RDTB agents in preclinical studies is due to decreased tumor growth rates and will likely be similar in the clinic; however, such manifestations are not readily detectable and quantifiable using nonrandomized clinical evaluations. To curtail the increasing rate of late-stage attrition of RDTB agents, which, if maintained, will stymie progress in cancer therapy, the design of initial nonrandomized evaluations, particularly the selection of tumors and patients, must be guided by the principal biological features of the agents. Next, evaluations, some of which must be randomized, can be performed in a wide range of tumor types, depending on the presence and relevance of the target. To validate the concept of RDTB therapeutics and to realize their full potential, radically different development, evaluation, and regulatory paradigms must be adopted.
Collapse
Affiliation(s)
- Eric K Rowinsky
- Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, Texas, USA.
| |
Collapse
|
60
|
Yang Y, Hong H, Zhang Y, Cai W. Molecular Imaging of Proteases in Cancer. CANCER GROWTH AND METASTASIS 2009; 2:13-27. [PMID: 20234801 DOI: 10.4137/cgm.s2814] [Citation(s) in RCA: 33] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
Proteases play important roles during tumor angiogenesis, invasion, and metastasis. Various molecular imaging techniques have been employed for protease imaging: optical (both fluorescence and bioluminescence), magnetic resonance imaging (MRI), single-photon emission computed tomography (SPECT), and positron emission tomography (PET). In this review, we will summarize the current status of imaging proteases in cancer with these techniques. Optical imaging of proteases, in particular with fluorescence, is the most intensively validated and many of the imaging probes are already commercially available. It is generally agreed that the use of activatable probes is the most accurate and appropriate means for measuring protease activity. Molecular imaging of proteases with other techniques (i.e. MRI, SPECT, and PET) has not been well-documented in the literature which certainly deserves much future effort. Optical imaging and molecular MRI of protease activity has very limited potential for clinical investigation. PET/SPECT imaging is suitable for clinical investigation; however the optimal probes for PET/SPECT imaging of proteases in cancer have yet to be developed. Successful development of protease imaging probes with optimal in vivo stability, tumor targeting efficacy, and desirable pharmacokinetics for clinical translation will eventually improve cancer patient management. Not limited to cancer, these protease-targeted imaging probes will also have broad applications in other diseases such as arthritis, atherosclerosis, and myocardial infarction.
Collapse
|
61
|
Oh KT, Oh YT, Oh NM, Kim K, Lee DH, Lee ES. A smart flower-like polymeric micelle for pH-triggered anticancer drug release. Int J Pharm 2009; 375:163-9. [DOI: 10.1016/j.ijpharm.2009.04.005] [Citation(s) in RCA: 45] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/12/2009] [Revised: 03/31/2009] [Accepted: 04/05/2009] [Indexed: 10/20/2022]
|
62
|
pH-sensitive properties of surface charge-switched multifunctional polymeric micelle. Int J Pharm 2009; 376:134-40. [PMID: 19394414 DOI: 10.1016/j.ijpharm.2009.04.021] [Citation(s) in RCA: 50] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/04/2009] [Revised: 04/14/2009] [Accepted: 04/16/2009] [Indexed: 12/22/2022]
Abstract
A surface charge-switched polymeric micelle with a pH signal was developed as a drug-carrying nanovehicle for tumor targeting. The micelles (particle size: approximately 85 nm), constructed from poly(L-lactic acid)-b-poly(ethylene glycol)-b-poly(L-lysine-N(epsilon)-(2,3-dimethyl maleic acid)) (PLA-b-PEG-b-PLys-DMA) and formed by self-assembly in an aqueous pH 7.4 solution, consisted of a hydrophobic core (PLA core) and two hydrophilic shells (PEG shell and PLys-DMA shell). An anionic charge can be built on the surface of the micelle at a physiological pH (approximately pH 7.4) due to 2,3-dimethyl maleic acid (DMA). However, DMA becomes chemically dissociated from the micelle under mild acidic conditions (pH 6.5-7.0) such as that found in solid tumors, which results in the formation of a cationic surface due to the poly(L-lysine) (PLys). This pH-triggered switch in surface charge may enhance cellular uptake of micelles to solid tumors, via an adsorptive endocytotic pathway due to the electrostatic interaction between micelles and cells. In addition, blending of the poly(L-histidine) (polyHis) into the hydrophobic core provides a mechanism for endosomal pH-triggered drug-release from the polymeric micelle. These combined properties of the polymeric micelle may aid in tumor-specific drug accumulation and allow it to be used as an effective treatment for tumors.
Collapse
|
63
|
Abstract
This review, containing over 276 references, covers the progress made in the chemistry and bioactivity of this important group of triterpenoids. Though initially known for their anti-inflammatory and anti-arthritic activities through a unique 5-LO inhibition mechanism, boswellic acids have recently attained significance due to their anti-cancer properties. The phytochemistry and chemical modifications, including mechanism of action, are discussed.
Collapse
Affiliation(s)
- Bhahwal Ali Shah
- Indian Institute of Integrative Medicine (CSIR), Canal Road, Jammu Tawi, 180001, India
| | | | | |
Collapse
|
64
|
Oh KT, Lee ES. Cancer-associated pH-responsive tetracopolymeric micelles composed of poly(ethylene glycol)-b-poly(L-histidine)-b-poly(L-lactic acid)-b-poly(ethylene glycol). POLYM ADVAN TECHNOL 2008. [DOI: 10.1002/pat.1228] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
65
|
Curran WJ, Schiller JH, Wolkin AC, Comis RL. Addressing the Current Challenges of Non–Small-Cell Lung Cancer Clinical Trial Accrual. Clin Lung Cancer 2008; 9:222-6. [PMID: 18650170 DOI: 10.3816/clc.2008.n.033] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Affiliation(s)
- Walter J Curran
- Department of Radiation Oncology, The Emory Clinic, Atlanta, GA 30322, USA.
| | | | | | | |
Collapse
|
66
|
Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, Sherman M, Schwartz M, Lotze M, Talwalkar J, Gores GJ. Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma. ACTA ACUST UNITED AC 2008; 100:698-711. [PMID: 18477802 DOI: 10.1093/jnci/djn134] [Citation(s) in RCA: 1307] [Impact Index Per Article: 81.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Affiliation(s)
- Josep M. Llovet
- Affiliations of authors: Mount Sinai Liver Cancer Program, Division of Liver Disease, Mount Sinai School of Medicine, New York, NY (JML, M. Schwartz); Barcelona Clínic Liver Cancer Group, Liver Unit, Hospital Clinic, CIBERehd, Institute for Biomedical Investigations August Pi Sunyer, Barcelona, Spain (JML, JB); Saint Louis University School of Medicine, St Louis, MO (AMDB); Office of Disease Prevention, National Institu
| | - Adrian M. Di Bisceglie
- Affiliations of authors: Mount Sinai Liver Cancer Program, Division of Liver Disease, Mount Sinai School of Medicine, New York, NY (JML, M. Schwartz); Barcelona Clínic Liver Cancer Group, Liver Unit, Hospital Clinic, CIBERehd, Institute for Biomedical Investigations August Pi Sunyer, Barcelona, Spain (JML, JB); Saint Louis University School of Medicine, St Louis, MO (AMDB); Office of Disease Prevention, National Institu
| | - Jordi Bruix
- Affiliations of authors: Mount Sinai Liver Cancer Program, Division of Liver Disease, Mount Sinai School of Medicine, New York, NY (JML, M. Schwartz); Barcelona Clínic Liver Cancer Group, Liver Unit, Hospital Clinic, CIBERehd, Institute for Biomedical Investigations August Pi Sunyer, Barcelona, Spain (JML, JB); Saint Louis University School of Medicine, St Louis, MO (AMDB); Office of Disease Prevention, National Institu
| | - Barnett S. Kramer
- Affiliations of authors: Mount Sinai Liver Cancer Program, Division of Liver Disease, Mount Sinai School of Medicine, New York, NY (JML, M. Schwartz); Barcelona Clínic Liver Cancer Group, Liver Unit, Hospital Clinic, CIBERehd, Institute for Biomedical Investigations August Pi Sunyer, Barcelona, Spain (JML, JB); Saint Louis University School of Medicine, St Louis, MO (AMDB); Office of Disease Prevention, National Institu
| | - Riccardo Lencioni
- Affiliations of authors: Mount Sinai Liver Cancer Program, Division of Liver Disease, Mount Sinai School of Medicine, New York, NY (JML, M. Schwartz); Barcelona Clínic Liver Cancer Group, Liver Unit, Hospital Clinic, CIBERehd, Institute for Biomedical Investigations August Pi Sunyer, Barcelona, Spain (JML, JB); Saint Louis University School of Medicine, St Louis, MO (AMDB); Office of Disease Prevention, National Institu
| | - Andrew X. Zhu
- Affiliations of authors: Mount Sinai Liver Cancer Program, Division of Liver Disease, Mount Sinai School of Medicine, New York, NY (JML, M. Schwartz); Barcelona Clínic Liver Cancer Group, Liver Unit, Hospital Clinic, CIBERehd, Institute for Biomedical Investigations August Pi Sunyer, Barcelona, Spain (JML, JB); Saint Louis University School of Medicine, St Louis, MO (AMDB); Office of Disease Prevention, National Institu
| | - Morris Sherman
- Affiliations of authors: Mount Sinai Liver Cancer Program, Division of Liver Disease, Mount Sinai School of Medicine, New York, NY (JML, M. Schwartz); Barcelona Clínic Liver Cancer Group, Liver Unit, Hospital Clinic, CIBERehd, Institute for Biomedical Investigations August Pi Sunyer, Barcelona, Spain (JML, JB); Saint Louis University School of Medicine, St Louis, MO (AMDB); Office of Disease Prevention, National Institu
| | - Myron Schwartz
- Affiliations of authors: Mount Sinai Liver Cancer Program, Division of Liver Disease, Mount Sinai School of Medicine, New York, NY (JML, M. Schwartz); Barcelona Clínic Liver Cancer Group, Liver Unit, Hospital Clinic, CIBERehd, Institute for Biomedical Investigations August Pi Sunyer, Barcelona, Spain (JML, JB); Saint Louis University School of Medicine, St Louis, MO (AMDB); Office of Disease Prevention, National Institu
| | - Michael Lotze
- Affiliations of authors: Mount Sinai Liver Cancer Program, Division of Liver Disease, Mount Sinai School of Medicine, New York, NY (JML, M. Schwartz); Barcelona Clínic Liver Cancer Group, Liver Unit, Hospital Clinic, CIBERehd, Institute for Biomedical Investigations August Pi Sunyer, Barcelona, Spain (JML, JB); Saint Louis University School of Medicine, St Louis, MO (AMDB); Office of Disease Prevention, National Institu
| | - Jayant Talwalkar
- Affiliations of authors: Mount Sinai Liver Cancer Program, Division of Liver Disease, Mount Sinai School of Medicine, New York, NY (JML, M. Schwartz); Barcelona Clínic Liver Cancer Group, Liver Unit, Hospital Clinic, CIBERehd, Institute for Biomedical Investigations August Pi Sunyer, Barcelona, Spain (JML, JB); Saint Louis University School of Medicine, St Louis, MO (AMDB); Office of Disease Prevention, National Institu
| | - Gregory J. Gores
- Affiliations of authors: Mount Sinai Liver Cancer Program, Division of Liver Disease, Mount Sinai School of Medicine, New York, NY (JML, M. Schwartz); Barcelona Clínic Liver Cancer Group, Liver Unit, Hospital Clinic, CIBERehd, Institute for Biomedical Investigations August Pi Sunyer, Barcelona, Spain (JML, JB); Saint Louis University School of Medicine, St Louis, MO (AMDB); Office of Disease Prevention, National Institu
| | | |
Collapse
|
67
|
Kosaihira A, Ona T. Rapid and quantitative method for evaluating the personal therapeutic potential of cancer drugs. Anal Bioanal Chem 2008; 391:1889-97. [DOI: 10.1007/s00216-008-2152-3] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/25/2008] [Revised: 04/18/2008] [Accepted: 04/18/2008] [Indexed: 12/11/2022]
|
68
|
Sobrero A, Andretta V. Small molecule inhibitors of tyrosine kinase: waiting for the good news in colorectal cancer as well. ACTA ACUST UNITED AC 2008; 31:224-5. [PMID: 18497509 DOI: 10.1159/000122265] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
69
|
Fenner MH, Beutel G, Grünwald V. Targeted therapies for patients with germ cell tumors. Expert Opin Investig Drugs 2008; 17:511-22. [DOI: 10.1517/13543784.17.4.511] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
|
70
|
Krohn KA, O'Sullivan F, Crowley J, Eary JF, Linden HM, Link JM, Mankoff DA, Muzi M, Rajendran JG, Spence AM, Swanson KR. Challenges in clinical studies with multiple imaging probes. Nucl Med Biol 2008; 34:879-85. [PMID: 17921038 DOI: 10.1016/j.nucmedbio.2007.07.014] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/21/2007] [Revised: 07/23/2007] [Accepted: 07/23/2007] [Indexed: 11/16/2022]
Abstract
This article addresses two related issues: (a) When a new imaging agent is proposed, how does the imager integrate it with other biomarkers, either sampled or imaged? (b) When we have multiple imaging agents, is the information additive or duplicative and how is this objectively determined? Molecular biology is leading to new treatment options with reduced normal tissue toxicity, and imaging should have a role in objectively evaluating new treatments. There are two roles for molecular characterization of disease. Molecular imaging measurements before therapy help predict the aggressiveness of disease and identify therapeutic targets and, therefore, help choose the optimal therapy for an individual. Measurements of specific biochemical processes made during or after therapy should be sensitive measures of tumor response. The rules of evidence are not fully developed for the prognostic role of imaging biomarkers, but the potential of molecular imaging provides compelling motivation to push forward with convincing validation studies. New imaging procedures need to be characterized for their effectiveness under realistic clinical conditions to improve the management of patients and achieve a better outcome. The purpose of this article is to promote a critical discussion within the molecular imaging community because our future value to the overall biomedical community will be in supporting better treatment outcomes rather than in detection.
Collapse
Affiliation(s)
- Kenneth A Krohn
- Radiology Department, Molecular Imaging Center, University of Washington, Seattle, WA 98195-6004, USA.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
71
|
Varela M, Golder M, Archer F, de las Heras M, Leroux C, Palmarini M. A large animal model to evaluate the effects of Hsp90 inhibitors for the treatment of lung adenocarcinoma. Virology 2007; 371:206-15. [PMID: 17961623 DOI: 10.1016/j.virol.2007.09.041] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2007] [Revised: 09/06/2007] [Accepted: 09/24/2007] [Indexed: 10/22/2022]
Abstract
Ovine pulmonary adenocarcinoma (OPA) is a naturally occurring lung cancer of sheep caused by Jaagsiekte sheep retrovirus (JSRV). The JSRV envelope glycoprotein (Env) functions as a dominant oncoprotein in vitro and in vivo. In order to develop the basis for the use of OPA as a lung cancer model, we screened a variety of signal transduction inhibitors for their ability to block transformation by the JSRV Env. Most inhibitors were not effective in blocking JSRV Env-induced transformation. On the contrary, various Hsp90 inhibitors efficiently blocked JSRV transformation. This phenomenon was at least partly due to Akt degradation, which is activated in JSRV-transformed cells. Hsp90 was found expressed in tumor cells of sheep with naturally occurring OPA. In addition, Hsp90 inhibitors specifically inhibited proliferation of immortalized and moreover primary cells derived from OPA tumors. Thus, OPA could be used as a large animal model for comprehensive studies investigating the effects of Hsp90 inhibitors in lung adenocarcinoma.
Collapse
Affiliation(s)
- Mariana Varela
- Institute of Comparative Medicine, University of Glasgow Veterinary School, 464 Bearsden Road, Glasgow, G61 1QH, Scotland, UK
| | | | | | | | | | | |
Collapse
|
72
|
Greystoke A, Hughes A, Ranson M, Dive C, Cummings J, Ward T. Serum biomarkers of apoptosis. EJC Suppl 2007. [DOI: 10.1016/s1359-6349(07)70032-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022] Open
|
73
|
Abstract
Most cancer deaths are due to the development of metastases, hence the most important improvements in morbidity and mortality will result from prevention (or elimination) of such disseminated disease. Some would argue that treatments directed against metastasis are too late because cells have already escaped from the primary tumour. Such an assertion runs contrary to the significant but (for many common adult cancers) fairly modest improvements in survival following the use of adjuvant radiation and chemotherapy designed to eliminate disseminated cells after surgical removal of the primary tumour. Nonetheless, the debate raises important issues concerning the accurate early identification of clonogenic, metastatic cells, the discovery of novel, tractable targets for therapy, and the monitoring of minimal residual disease. We focus on recent findings regarding intrinsic and extrinsic molecular mechanisms controlling metastasis that determine how, when, and where cancers metastasise, and their implications for patient management in the 21st century.
Collapse
Affiliation(s)
- Suzanne A Eccles
- Tumour Biology and Metastasis, Cancer Research UK Centre for Cancer Therapeutics, Institute of Cancer Research, Sutton, UK.
| | | |
Collapse
|
74
|
Danson S, Ranson M, Denneny O, Cummings J, Ward TH. Validation of the comet-X assay as a pharmacodynamic assay for measuring DNA cross-linking produced by the novel anticancer agent RH1 during a phase I clinical trial. Cancer Chemother Pharmacol 2007; 60:851-61. [PMID: 17333193 DOI: 10.1007/s00280-007-0432-9] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/21/2006] [Accepted: 01/22/2007] [Indexed: 11/27/2022]
Abstract
PURPOSE RH1 is a novel anticancer agent with potent DNA-cross linking activity. RH1 has the potential to be activated within tumors over expressing NQO1, giving maximal antitumour activity with reduced toxicity in normal tissues. RH1 has recently completed a Cancer Research UK sponsored phase I clinical trial at two different centers in the United Kingdom. The comet-X assay was a secondary endpoint in this trial and assay validation was necessary. We describe here this validation process. Whilst it is impossible to cover all variations/conditions of a pharmacodynamic assay, we have strived to evaluate and demonstrate that this assay conforms to the three R's of validation, that is robustness, reliability and reproducibility. METHODS K562 and peripheral blood mononuclear cells were treated with either radiation alone, or with a combination of radiation and drug. These samples were then embedded in low melting point agarose and subjected to a modified version of the alkaline single cell gel electrophoresis (Comet) assay, described here as the comet-X assay. Variations in the preparation, electrophoresis, storage and scoring of these samples was investigated. In addition radiation and drug dose response curves were constructed. Finally stability of QC standards was investigated over a 30-month period. RESULTS We have demonstrated a linear radiation-dose response in cells up to 20 Gy and drug induced DNA cross-linking up to 50 nM. From the radiation dose response curves we were able to show that the relative inaccuracy measured against a global mean value was less than 25% and the relative (within day) imprecision was less than 30% over all doses. Between day runs produced an intra assay imprecision of 21.2%. Variables involved in the electrophoresis process showed the voltage across all slides in the tank ranged from 3.1 to -2.0 (mV) whilst the current ranged from 0.8-5.5 mA. QC standards were prepared from PBMCs of healthy donors and frozen at -80 degrees C. The stability of these frozen QC standards was measured over a 30-month period. No significant deterioration in any of the control, irradiated or drug treated samples was observed. CONCLUSIONS The comet-X assay has been shown to be a robust, reliable and reproducible assay. It is ideally suited for the evaluation of the pharmacodynamic effects of DNA cross-linking agents undergoing early clinical trials. Furthermore, this assay may provide valuable data, in conjunction with pharmacokinetics, when measuring toxicity and efficacy as part of the RH1 phase I clinical trial.
Collapse
Affiliation(s)
- S Danson
- Clinical and Experimental Pharmacology, Paterson Institute for Cancer Research, University of Manchester, Paterson Laboratories, Wilmslow Road, Manchester, M20 4BX, UK
| | | | | | | | | |
Collapse
|
75
|
Kummar S, Kinders R, Rubinstein L, Parchment RE, Murgo AJ, Collins J, Pickeral O, Low J, Steinberg SM, Gutierrez M, Yang S, Helman L, Wiltrout R, Tomaszewski JE, Doroshow JH. Compressing drug development timelines in oncology using phase '0' trials. Nat Rev Cancer 2007; 7:131-9. [PMID: 17251919 DOI: 10.1038/nrc2066] [Citation(s) in RCA: 170] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
The optimal evaluation of molecularly targeted anticancer agents requires the integration of pharmacodynamic assays into early clinical investigations. Phase '0' trials conducted under the new Exploratory Investigational New Drug Guidance from the US Food and Drug Administration can provide a platform to establish the feasibility of assays for target modulation in human samples, evaluate biomarkers for drug effects and provide pharmacokinetic data. Phase 0 trials could facilitate rational drug selection, identify therapeutic failures early, and might compress timelines for anticancer drug development. We expect that such trials will become a routine part of early-phase oncological drug development in the future.
Collapse
Affiliation(s)
- Shivaani Kummar
- Center for Cancer Research, SAIC-Frederick, Inc., NCI-Frederick, Frederick, Maryland, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
76
|
Watters JW, Roberts CJ. Developing gene expression signatures of pathway deregulation in tumors. Mol Cancer Ther 2007; 5:2444-9. [PMID: 17041087 DOI: 10.1158/1535-7163.mct-06-0340] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023]
Abstract
Recent advances in our understanding of cancer biology have led to the development of therapies targeting specific signaling pathways. Molecular targeting promises to improve our ability to predict who will respond by assessing the state of these targeted pathways in patients. However, a single pathway can be deregulated by multiple mechanisms, and for some pathways it may be difficult to assess activation state by analyzing a single oncogene or tumor suppressor. Therefore, developing gene expression signatures of pathway activation status using model systems or human tumor samples may enable a more reliable measurement of pathway activity. This review discusses recent advances in the identification of gene expression-based signatures of pathway deregulation and how this information may lead to improved therapeutic response prediction.
Collapse
Affiliation(s)
- James W Watters
- Department of Molecular Profiling, Merck Research Laboratories, West Point, Pennsylvania, USA
| | | |
Collapse
|
77
|
Oh KT, Yin H, Lee ES, Bae YH. Polymeric nanovehicles for anticancer drugs with triggering release mechanisms. ACTA ACUST UNITED AC 2007. [DOI: 10.1039/b707142f] [Citation(s) in RCA: 162] [Impact Index Per Article: 9.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
|
78
|
Dilts DM, Sandler AB, Baker M, Cheng SK, George SL, Karas KS, McGuire S, Menon GS, Reusch J, Sawyer D, Scoggins M, Wu A, Zhou K, Schilsky RL. Processes to activate phase III clinical trials in a Cooperative Oncology Group: the Case of Cancer and Leukemia Group B. J Clin Oncol 2006; 24:4553-7. [PMID: 17008694 DOI: 10.1200/jco.2006.06.7819] [Citation(s) in RCA: 64] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
PURPOSE National Cancer Institute-sponsored cooperative oncology groups are major sponsors of phase III clinical trials, yet the time and steps required to design and activate such studies has not been well studied. We examine the processes and document the calendar time required to activate such studies opened by the Cancer and Leukemia Group B (CALGB). METHODS Setup steps were documented by (1) interviewing CALGB headquarters and statistical center staff and committee chairs to discover the steps required to transit from concept development to final study activation, (2) reviewing procedure manuals, and (3) inspecting all study records, documents, and e-mails to identify any additional steps. Calendar time was collected for each major process. RESULTS Thirteen phase III studies were activated by CALGB during the study period of May 2002 to May 2005. More than 370 distinct processes were required for study activation: 317 work steps, 42 decision points, and 29 processing loops. Sixty-three percent of the decision points were outside CALGB. The complete process map measures 243.5" x 41" in 8-point font. Median calendar days to activate a phase III study at CALGB was 580 days (range, 295 to 1,248 days) from concept approval and 784 days (range, 537 to 1,130 days) from initial conception of the study. CONCLUSION Setup of a phase III study at a major cooperative oncology group is a complex and lengthy process, with the majority of decision points external to the cooperative group. To improve the activation process, research should to be directed toward both internal and external groups and processes.
Collapse
Affiliation(s)
- David M Dilts
- Center for Management Research in Healthcare, Vanderbilt University, Nashville, TN, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
79
|
Dilts DM, Sandler AB. Invisible barriers to clinical trials: the impact of structural, infrastructural, and procedural barriers to opening oncology clinical trials. J Clin Oncol 2006; 24:4545-52. [PMID: 17008693 DOI: 10.1200/jco.2005.05.0104] [Citation(s) in RCA: 126] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
PURPOSE To investigate the administrative barriers that impact the opening of clinical trials at the Vanderbilt-Ingram Cancer Center (VICC) and at VICC Affiliate Network (VICCAN) sites. METHODS VICC, a National Cancer Institute-designated comprehensive cancer center, and three VICCAN community practice sites were studied. Methodology used was identification and mapping of existing processes and analysis of historical timing data. RESULTS At course granularity, the process steps required at VICC and VICCAN main office plus local sites are 20 v 17 to 30 steps, respectively; this gap widens with finer granularity, with more than 110 v less than 60 steps, respectively. Approximately 50% of the steps are nonvalue added. For example, in the institutional review board (IRB) process, less than one third of the steps add value to the final protocol. The numbers of groups involved in the approval processes are 27 (VICC) and 6 to 14 (VICCAN home office and local sites). The median times to open a trial are 171 days (95% CI, 158 to 182 days) for VICC and 191 days (95% CI, 119 to 269 days) for the VICCAN sites. Contrary to expectations, the time for IRB review and approval (median, 47 days) is the fastest process compared with the scientific review committee review and approval (median, 70 days) and contracts and grants review (median, 78.5 days). Opening a cooperative group clinical trial is significantly (P = .05) more rapid because they require fewer review steps. CONCLUSION There are numerous opportunities to remove nonvalue-added steps and save time in opening clinical trials. With increasing numbers of new agents, fewer domestic principal investigators, and more companies off-shoring clinical trials, overcoming such barriers is of critical importance for maintenance of core oncology research capabilities in the United States.
Collapse
Affiliation(s)
- David M Dilts
- Center for Management Research in Healthcare, Vanderbilt University, Nashville, TN, USA.
| | | |
Collapse
|
80
|
Bueno Muíño C, García-Sáenz JA, López Tarruella S, Rodríguez Lajustica L, Díaz-Rubio E. New target-based agents involve new clinical trial designs. Clin Transl Oncol 2006; 8:581-7. [PMID: 16952846 DOI: 10.1007/s12094-006-0063-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
Abstract
Clinical cancer investigation is performed through clinical trials. Development and measurement of clinical efficacy of new target-based agents differs from classic cytotoxic drugs. Whereas the aim of chemotherapy drugs is to destroy tumoral cells, new agents try to inhibit cell profileration without a clear tumor shrinkage. The main endpoint for phase I trials is to determine the optimal biological response with the least toxicity; oncopharmacogenomic studies must be performed in tumoral biopsies to assess the target inhibition. Time to progression and biological activity are the endpoints for phase II studies. Finally, phase III trials will determine overall survival.
Collapse
Affiliation(s)
- Coralia Bueno Muíño
- Servicio de Oncología Médica, Hospital Clínico Universitario San Carlos, Madrid, Spain
| | | | | | | | | |
Collapse
|
81
|
Kummar S, Gutierrez M, Doroshow JH, Murgo AJ. Drug development in oncology: classical cytotoxics and molecularly targeted agents. Br J Clin Pharmacol 2006; 62:15-26. [PMID: 16842375 PMCID: PMC1885070 DOI: 10.1111/j.1365-2125.2006.02713.x] [Citation(s) in RCA: 127] [Impact Index Per Article: 7.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2006] [Accepted: 04/26/2006] [Indexed: 11/29/2022] Open
Abstract
There is an apparent need to improve the speed and efficiency of oncological drug development. Furthermore, strategies traditionally applied to the development of standard cytotoxic chemotherapy may not be appropriate for molecularly targeted agents. This is particularly the case for exploratory Phase 1 and 2 trials. Conventional approaches to determine dose based on maximum tolerability and efficacy based on objective tumour response may not be suitable for targeted agents, since many of them have a wide therapeutic index and inhibit tumour growth without demonstrable cytotoxicity. Instead, exploratory trials of targeted agents may have to focus on other end-points such as pharmacological effects and disease stabilization. Thus, there is an increasing interest in making the best possible use of biomarkers and pharmacogenomics in early phases of drug development.
Collapse
Affiliation(s)
- Shivaani Kummar
- Medical Oncology Branch, Center for Cancer Research and Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD 20892, USA
| | | | | | | |
Collapse
|
82
|
Jankowski JA, Hawk ET. A methodologic analysis of chemoprevention and cancer prevention strategies for gastrointestinal cancer. ACTA ACUST UNITED AC 2006; 3:101-11. [PMID: 16456576 DOI: 10.1038/ncpgasthep0412] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/02/2005] [Accepted: 11/22/2005] [Indexed: 12/31/2022]
Abstract
Gastroenterology lags behind other specialties such as cardiology in the quality of its evidence base for clinical practice. One area where this is particularly evident is in cancer prevention, despite developments in chemoprevention strategies for high-risk patients. For chemoprevention strategies to be successful, we need appropriate clinical networks and translational science infrastructures, model chemoprevention agents and multiple, large, flexible and randomized clinical trials. Translational science must also be embedded into large-scale, long-term, randomized clinical trials that have hard endpoints, so that irrefutable evidence of the longevity of treatment efficacy can be gathered. We also need to be able to identify an individual's cancer risk using valid global patient populations, so that medical benefits can be applied to all, regardless of ethnicity, sex, economic status, age and comorbidities. The future success of gastrointestinal chemoprevention relies on fostering a closer link between basic pharmaceutical research and clinical applications, in a 'bench to bedside and back' manner. In this review we systematically assess the evidence for various cancer prevention strategies, especially chemoprevention, and highlight the obstacles to further exploitation of this knowledge base.
Collapse
Affiliation(s)
- Janusz A Jankowski
- Department of Clinical Pharmacology, Radcliffe Infirmary, Oxford University, UK.
| | | |
Collapse
|
83
|
Haney SA. Anticancer drug development incorporating high-content screening and RNAi: synergistic approaches to improve target identification and validation. Expert Opin Drug Discov 2006; 1:19-29. [DOI: 10.1517/17460441.1.1.19] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
84
|
Ding J, Miao ZH, Meng LH, Geng MY. Emerging cancer therapeutic opportunities target DNA-repair systems. Trends Pharmacol Sci 2006; 27:338-44. [PMID: 16697054 DOI: 10.1016/j.tips.2006.04.007] [Citation(s) in RCA: 94] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/08/2005] [Revised: 03/07/2006] [Accepted: 04/24/2006] [Indexed: 12/18/2022]
Abstract
DNA-damaging agents have a central role in non-surgical cancer treatment. The balance between DNA damage and repair determines the final therapeutic consequences. An elevated DNA-repair capacity in tumor cells leads to drug or radiation resistance and severely limits the efficacy of these agents. Interference with DNA repair has emerged as an important approach in combination therapy against cancer. Anticancer targets in DNA-repair systems have emerged, against which several small-molecule compounds are currently undergoing clinical trials.
Collapse
Affiliation(s)
- Jian Ding
- Division of Antitumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai 201203, China.
| | | | | | | |
Collapse
|
85
|
Zalutsky MR. Potential of Immuno–Positron Emission Tomography for Tumor Imaging and Immunotherapy Planning. Clin Cancer Res 2006; 12:1958-60. [PMID: 16609003 DOI: 10.1158/1078-0432.ccr-06-0405] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
86
|
Freidlin B, Simon R. Adaptive signature design: an adaptive clinical trial design for generating and prospectively testing a gene expression signature for sensitive patients. Clin Cancer Res 2006; 11:7872-8. [PMID: 16278411 DOI: 10.1158/1078-0432.ccr-05-0605] [Citation(s) in RCA: 284] [Impact Index Per Article: 15.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/24/2023]
Abstract
PURPOSE A new generation of molecularly targeted agents is entering the definitive stage of clinical evaluation. Many of these drugs benefit only a subset of treated patients and may be overlooked by the traditional, broad-eligibility approach to randomized clinical trials. Thus, there is a need for development of novel statistical methodology for rapid evaluation of these agents. EXPERIMENTAL DESIGN We propose a new adaptive design for randomized clinical trials of targeted agents in settings where an assay or signature that identifies sensitive patients is not available at the outset of the study. The design combines prospective development of a gene expression-based classifier to select sensitive patients with a properly powered test for overall effect. RESULTS Performance of the adaptive design, relative to the more traditional design, is evaluated in a simulation study. It is shown that when the proportion of patients sensitive to the new drug is low, the adaptive design substantially reduces the chance of false rejection of effective new treatments. When the new treatment is broadly effective, the adaptive design has power to detect the overall effect similar to the traditional design. Formulas are provided to determine the situations in which the new design is advantageous. CONCLUSION Development of a gene expression-based classifier to identify the subset of sensitive patients can be prospectively incorporated into a randomized phase III design without compromising the ability to detect an overall effect.
Collapse
Affiliation(s)
- Boris Freidlin
- Biometric Research Branch, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD 20892, USA.
| | | |
Collapse
|
87
|
Abstract
The search for an MMP inhibitor with anticancer efficacy is a nearly three-decade endeavor. This inhibitor is yet to be found. The reasons for this failure include shortcomings in the chemistry of these compounds (including broad MMP sub-type selectivity, metabolic lability, and toxicity) as well as the emerging, and arguably extraordinary, complexity of MMP cell (and cancer) biology. Together these suggest that the successful anticancer inhibitor must possess MMP selectivity against the MMP subtype whose involvement is critical, yet highly temporally (with respect to metastatic progression) and mechanistically (with respect to matrix degradation) regulated. This review summarizes the progression of chemical structure and mechanistic thinking toward these objectives, with emphasis on the disappointment, the perseverance, and the resilient optimism that such an inhibitor is there to be discovered.
Collapse
Affiliation(s)
- Jed F Fisher
- Department of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, IN 46556-5670, USA
| | | |
Collapse
|
88
|
Shen Y, Senzer N, Nemunaitis J. Individualised cancer therapeutics: dream or reality? Therapeutics construction. Expert Opin Biol Ther 2005; 5:1427-41. [PMID: 16255647 DOI: 10.1517/14712598.5.11.1427] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
The analysis of DNA microarray and proteomic data, and the subsequent integration into functional expression sets, provides a circuit map of the hierarchical cellular networks responsible for sustaining the viability and environmental competitiveness of cancer cells, that is, their robust systematics. These technologies can be used to 'snapshot' the unique patterns of molecular derangements and modified interactions in cancer, and allow for strategic selection of therapeutics that best match the individual profile of the tumour. This review highlights technology that can be used to selectively disrupt critical molecular targets and describes possible vehicles to deliver the synthesised molecular therapeutics to the relevant cellular compartments of the malignant cells. RNA interference (RNAi) involves a group of evolutionarily conserved gene silencing mechanisms in which small sequences of double-stranded RNA or intrinsic antisense RNA trigger mRNA cleavage or translational repression, respectively. Although RNAi molecules can be synthesised to 'silence' virtually any gene, even if upregulated, a mechanism for selective delivery of RNAi effectors to sites of malignant disease remains challenging. The authors will discuss gene-modified conditionally replicating viruses as candidate vehicles for the delivery of RNAi.
Collapse
Affiliation(s)
- Yuqiao Shen
- Mary Crowley Medical Research Center, Dallas, TX 75201, USA
| | | | | |
Collapse
|
89
|
Raikwar SP, Temm CJ, Raikwar NS, Kao C, Molitoris BA, Gardner TA. Adenoviral vectors expressing human endostatin-angiostatin and soluble Tie2: enhanced suppression of tumor growth and antiangiogenic effects in a prostate tumor model. Mol Ther 2005; 12:1091-100. [PMID: 16169279 PMCID: PMC2763308 DOI: 10.1016/j.ymthe.2005.07.690] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/16/2004] [Revised: 07/19/2005] [Accepted: 07/22/2005] [Indexed: 01/02/2023] Open
Abstract
Angiogenesis is essential for prostate cancer development and metastasis. Antiangiogenic therapy targeting tumor neovasculature, therefore, represents a promising approach for prostate cancer treatment. We hypothesized that adenoviral-mediated delivery of a combination of antiangiogenic factors might have an enhanced antitumor response. We developed the adenoviral vectors Ad-hEndo-angio, expressing a unique, chimeric human endostatin-angiostatin fusion protein, and Ad-sTie2, expressing a soluble form of endothelium-specific receptor tyrosine kinase Tie2. Matrigel angiogenesis assays using Ad-hEndo-angio revealed significant inhibition of tubular network formation and endothelial sprouting compared to Ad-sTie2. In vivo studies in a bilateral PC-3 tumor xenograft model following either intratumoral or systemic administration of Ad-hEndo-angio led to enhanced tumor growth suppression compared to Ad-sTie2. A novel finding is that an intratumoral, combination therapy employing one-half the dose of Ad-hEndo-angio as well as Ad-sTie2 led to a complete regression of the injected, as well as the contralateral uninjected, tumor and prolonged the tumor-free survival in 80% of the animals. In addition, a novel, real-time, intravital imaging modality was used to monitor antiangiogenic responses following adenoviral-mediated gene transfer. These results suggest that a combinatorial antiangiogenic gene therapy approach involving Ad-hEndo-angio and Ad-sTie2 could become a novel form of treatment for localized human prostate cancer.
Collapse
Affiliation(s)
- Sudhanshu P. Raikwar
- Department of Urology, Indiana University School of Medicine, Indianapolis, IN 46202, USA
- Department of Microbiology & Immunology, Indiana University School of Medicine, Indianapolis, IN 46202, USA
- George M. O’Brien Center for Advanced Renal Microscopic Analysis, Indiana University School of Medicine, Indianapolis, IN 46202, USA
- Walther Oncology Center, Indiana University School of Medicine, Indianapolis, IN 46202, USA
| | - Constance J. Temm
- Department of Medicine, Indiana University School of Medicine, Indianapolis, IN 46202, USA
- Indiana Center for Vascular Biology and Medicine, Indiana University School of Medicine, Indianapolis, IN 46202, USA
| | - Nandita S. Raikwar
- Department of Medicine, Indiana University School of Medicine, Indianapolis, IN 46202, USA
- Division of Endocrinology, Richard L. Roudebush VA Medical Center, Indiana University School of Medicine, Indianapolis, IN 46202, USA
| | - Chinghai Kao
- Department of Urology, Indiana University School of Medicine, Indianapolis, IN 46202, USA
- Department of Microbiology & Immunology, Indiana University School of Medicine, Indianapolis, IN 46202, USA
- George M. O’Brien Center for Advanced Renal Microscopic Analysis, Indiana University School of Medicine, Indianapolis, IN 46202, USA
- Walther Oncology Center, Indiana University School of Medicine, Indianapolis, IN 46202, USA
| | - Bruce A. Molitoris
- Department of Medicine, Indiana University School of Medicine, Indianapolis, IN 46202, USA
- Division of Nephrology, Indiana University School of Medicine, Indianapolis, IN 46202, USA
- George M. O’Brien Center for Advanced Renal Microscopic Analysis, Indiana University School of Medicine, Indianapolis, IN 46202, USA
| | - Thomas A. Gardner
- Department of Urology, Indiana University School of Medicine, Indianapolis, IN 46202, USA
- Department of Microbiology & Immunology, Indiana University School of Medicine, Indianapolis, IN 46202, USA
- George M. O’Brien Center for Advanced Renal Microscopic Analysis, Indiana University School of Medicine, Indianapolis, IN 46202, USA
- Walther Oncology Center, Indiana University School of Medicine, Indianapolis, IN 46202, USA
- To whom correspondence and reprint requests should be addressed at the Department of Urology, RT 420, Indiana University School of Medicine, 535 Barnhill Drive, Indianapolis, IN 46202, USA. Fax: +1 317 278 3432. E-mail:
| |
Collapse
|
90
|
Abstract
Purpose Single-arm phase II trials may not be appropriate for testing cytostatic agents. We evaluate two kinds of randomized designs for the early development of target-based cytostatic agents. Methods We compared power of the randomized discontinuation and upfront randomization designs under two models for the treatment effect of targeted cytostatic agents. Results The randomized discontinuation design is not as efficient as upfront randomization if treatment has a fixed effect on tumor growth rate or if treatment benefit is restricted to slower-growing tumors. On the other hand, the randomized discontinuation design can be advantageous under a model where only a subset of patients, those expressing the molecular target, is sensitive to the agent. To achieve efficiency, the design parameters must be carefully structured to provide adequate enrichment of the randomly assigned patients. Conclusion With careful planning, the randomized discontinuation designs can be useful in some settings in the early development of targeted agents where a reliable assay to select patients expressing the target is not available.
Collapse
Affiliation(s)
- Boris Freidlin
- Biometric Research Branch, National Cancer Institute, Bethesda, MD 20892-7434, USA.
| | | |
Collapse
|
91
|
Affiliation(s)
- Daniela S Krause
- Molecular Oncology Research Institute, Division of Hematology-Oncology, Tufts-New England Medical Center, Boston, MA 02111, USA
| | | |
Collapse
|
92
|
Abstract
Pathologic angiogenesis induced by a tumor is essential for its survival. The promise of tumor inhibition by targeting angiogenesis over the past several years has translated into numerous ongoing clinical trials. Recently, in a phase III trial involving patients with metastatic colorectal cancer, Bevacizumab (Genentech, Inc, San Francisco, CA), a recombinant humanized monoclonal antibody against vascular endothelial growth factor used in conjunction with standard chemotherapy was shown to increase survival, progression-free survival, response rate, and duration of response compared to chemotherapy alone. Thus far, duration of the increased response remains less than 6 months. The majority of deaths in patients with colorectal cancer are related to hepatic metastases. It is hoped that novel approaches directed at the complex interactions between tumor and microenvironment in the angiogenic process will strengthen the therapeutic armamentarium against hepatic malignancies.
Collapse
Affiliation(s)
- Shiva Sarraf-Yazdi
- Department of Surgery, Duke University Medical Center, DUMC, 3247, Durham, N.C. 27710, USA
| | | | | |
Collapse
|
93
|
Mocellin S, Provenzano M, Rossi CR, Pilati P, Nitti D, Lise M. DNA array-based gene profiling: from surgical specimen to the molecular portrait of cancer. Ann Surg 2005; 241:16-26. [PMID: 15621987 PMCID: PMC1356842 DOI: 10.1097/01.sla.0000150157.83537.53] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
Cancer is a heterogeneous disease in most respects, including its cellularity, different genetic alterations, and diverse clinical behaviors. Traditional molecular analyses are reductionist, assessing only 1 or a few genes at a time, thus working with a biologic model too specific and limited to confront a process whose clinical outcome is likely to be governed by the combined influence of many genes. The potential of functional genomics is enormous, because for each experiment, thousands of relevant observations can be made simultaneously. Accordingly, DNA array, like other high-throughput technologies, might catalyze and ultimately accelerate the development of knowledge in tumor cell biology. Although in its infancy, the implementation of DNA array technology in cancer research has already provided investigators with novel data and intriguing new hypotheses on the molecular cascade leading to carcinogenesis, tumor aggressiveness, and sensitivity to antiblastic agents. Given the revolutionary implications that the use of this technology might have in the clinical management of patients with cancer, principles of DNA array-based tumor gene profiling need to be clearly understood for the data to be correctly interpreted and appreciated. In the present work, we discuss the technical features characterizing this powerful laboratory tool and review the applications so far described in the field of oncology.
Collapse
Affiliation(s)
- Simone Mocellin
- Surgery Branch, Department of Oncological and Surgical Sciences, University of Padova, Italy.
| | | | | | | | | | | |
Collapse
|
94
|
Cummings J, Ward TH, Ranson M, Dive C. Apoptosis pathway-targeted drugs--from the bench to the clinic. Biochim Biophys Acta Rev Cancer 2005; 1705:53-66. [PMID: 15585173 DOI: 10.1016/j.bbcan.2004.09.005] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
It is an exciting time for cancer researchers in the field of apoptotic cell death. The avalanche of discoveries over the past decade or so regarding how apoptosis is regulated begins to be exploited for therapeutic benefit as the first apoptosis-targeted drugs enter early clinical trials. This chapter provides a selective review on the development of such drugs. We also outline issues regarding the regulation and design of early clinical trials of this type of molecularly targeted agent. Finally, we discuss the biomarkers and surrogate pharmacodynamic endpoint assays currently available to chart the efficacy of apoptosis-inducing anticancer therapy.
Collapse
Affiliation(s)
- Jeff Cummings
- Clinical and Experimental Pharmacology Group, Cancer Research UK Paterson Institute, Wilmslow Road, Manchester M20 4BX, UK
| | | | | | | |
Collapse
|
95
|
Zwierzina H, Borner M. Klinische Entwicklung zielgerichteter molekularer Krebstherapeutika. ACTA ACUST UNITED AC 2005; 28 Suppl 4:35-9. [PMID: 16205104 DOI: 10.1159/000088827] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Affiliation(s)
- Heinz Zwierzina
- Medizinische Klinik, Universitätsklinik Innsbruck, Innsbruck, Austria
| | | |
Collapse
|
96
|
Oliner J, Min H, Leal J, Yu D, Rao S, You E, Tang X, Kim H, Meyer S, Han SJ, Hawkins N, Rosenfeld R, Davy E, Graham K, Jacobsen F, Stevenson S, Ho J, Chen Q, Hartmann T, Michaels M, Kelley M, Li L, Sitney K, Martin F, Sun JR, Zhang N, Lu J, Estrada J, Kumar R, Coxon A, Kaufman S, Pretorius J, Scully S, Cattley R, Payton M, Coats S, Nguyen L, Desilva B, Ndifor A, Hayward I, Radinsky R, Boone T, Kendall R. Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2. Cancer Cell 2004; 6:507-16. [PMID: 15542434 DOI: 10.1016/j.ccr.2004.09.030] [Citation(s) in RCA: 344] [Impact Index Per Article: 17.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/21/2004] [Revised: 08/13/2004] [Accepted: 09/16/2004] [Indexed: 11/19/2022]
Abstract
Angiopoietin-2 (Ang2) exhibits broad expression in the remodeling vasculature of human tumors but very limited expression in normal tissues, making it an attractive candidate target for antiangiogenic cancer therapy. To investigate the functional consequences of blocking Ang2 activity, we generated antibodies and peptide-Fc fusion proteins that potently and selectively neutralize the interaction between Ang2 and its receptor, Tie2. Systemic treatment of tumor-bearing mice with these Ang2-blocking agents resulted in tumor stasis, followed by elimination of all measurable tumor in a subset of animals. These effects were accompanied by reduced endothelial cell proliferation, consistent with an antiangiogenic therapeutic mechanism. Anti-Ang2 therapy also prevented VEGF-stimulated neovascularization in a rat corneal model of angiogenesis. These results imply that specific Ang2 inhibition may represent an effective antiangiogenic strategy for treating patients with solid tumors.
Collapse
|
97
|
Abstract
Tumor angiogenesis is essential for tumor growth and progression. Therefore, targeting tumor blood vessels is a promising approach for cancer therapy. Angiogenesis, the formation of blood vessels, is a multistep process, and strongly influenced by the microenvironment. There are no in vitro assays that can resemble this dynamic process in vivo. For this reason, animal models and imaging technologies are critical for studying tumor angiogenesis, identifying therapeutic targets as well as validating the targets. Non-invasive molecular imaging in animal models presents an unprecedented opportunity and ability for us to perform repetitive observations and analysis of the biological processes underlying tumor angiogenesis and tumor progression in living animals in real time. As we gain a better understanding of the fundamental molecular nature of cancer, these techniques will be an important adjunct in translating the knowledge into clinical practice. This important information may elucidate how the tumor blood vessels behave and respond to certain treatments and therapies.
Collapse
Affiliation(s)
- Pengnain Charles Lin
- Department of Radiation Oncology, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee 37232, USA.
| |
Collapse
|
98
|
|
99
|
Chan-Hui PY, Stephens K, Warnock RA, Singh S. Applications of eTag™ assay platform to systems biology approaches in molecular oncology and toxicology studies. Clin Immunol 2004; 111:162-74. [PMID: 15137949 DOI: 10.1016/j.clim.2003.12.015] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2003] [Accepted: 12/23/2003] [Indexed: 02/02/2023]
Abstract
We have developed a universal eTag trade mark multiplex assay platform that can be uniquely applied to survey the molecule profiles of biologic systems in sub-global large-scale analyses. The effectiveness of eTag trade mark assays when applied to focused system biology studies in molecular oncology and predictive toxicology is herein described while reviewing the current methods commonly used. The multi-analyte and multi-parameter assay approach for parallel analysis will form the basis of an emerging paradigm of multiplexed molecular profiling for signaling pathway networks and various aspects of drug development processes.
Collapse
Affiliation(s)
- P-Y Chan-Hui
- Aclara BioSciences, Inc., Mountain View, CA 94043, USA
| | | | | | | |
Collapse
|
100
|
Abstract
Significant advances in the treatment of lung cancers, especially advanced-stage non-small cell lung cancer, have been marginal despite decades of intensive basic research and clinical trial testing. Among the newest class of promising drugs being tested is the angiogenesis inhibitor. The recent success of a randomized phase III trial testing an antivascular endothelial growth factor (VEGF) antibody with chemotherapy for the treatment of metastatic colon cancer has raised hopes that antiangiogenic drugs will have similar benefits for the treatment of lung cancer. Ironically, the sheer number and diversity of such drugs makes selecting the most promising candidates difficult. More detailed and definitive information on the specific factors that induce angiogenesis in types of lung cancer, such as the relative importance of VEGF or other proangiogenic growth factors in non-small cell lung cancer, small cell lung cancer, and mesothelioma angiogenesis, is therefore clearly needed. The nonangiogenic phenotype of some non-small cell lung cancers may render this subset particularly difficult to treat with angiogenesis inhibitors; such tumors, however, may be promising candidates for acute-acting vascular-targeting agents. As with other types of cancer, success with angiogenesis inhibitors will no doubt depend on a number of factors including screening patients' tumors for presence or absence of a particular drug target (eg, bioactive VEGF receptor-2 bound VEGF) when targeting VEGF, selecting the optimal biologic/therapeutic doses of antiangiogenic drugs, monitoring antiangiogenic drug activity in tumors, and determining optimal combinations to use with chemotherapy regimens.
Collapse
Affiliation(s)
- Robert S Kerbel
- Department of Medical Biophysics, Sunnybrook and Women's College Health Sciences Centre, Toronto-Sunnybrook Regional Cancer Centre, Ontario
| |
Collapse
|